105 related articles for article (PubMed ID: 31078629)
1. A Complex Renal Cyst in a Patient on Crizotinib: Case Report.
Liaw CW; Palese M; Fabrizio LD
Urology; 2019 Sep; 131():21-23. PubMed ID: 31078629
[No Abstract] [Full Text] [Related]
2. Crizotinib-Associated Renal Cysts in Anaplastic Lymphoma Kinase-Positive Lung Cancer Patients: A Single-Center Experience.
Eiamprapaporn P; Mungwatthana N; Twinprai P; Sookprasert A; Chindaprasirt J; Ahooja A; Watthanaudomrot S; Sirithanaphol W
Urol Int; 2020; 104(3-4):269-272. PubMed ID: 31480046
[TBL] [Abstract][Full Text] [Related]
3. Renal Injury during Long-Term Crizotinib Therapy.
Yasuma T; Kobayashi T; D'Alessandro-Gabazza CN; Fujimoto H; Ito K; Nishii Y; Nishihama K; Baffour Tonto P; Takeshita A; Toda M; Gabazza EC; Taguchi O; Yonemura S; Hataji O
Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30257437
[TBL] [Abstract][Full Text] [Related]
4. Crizotinib-associated Renal Cyst Formation in a Pediatric Patient With ALK+ Epithelioid Inflammatory Myofibroblastic Sarcoma.
Kopelevich A; Holzman SA; La J; Lai HA; Torno L; Stephany HA
Urology; 2021 Mar; 149():222-224. PubMed ID: 32882306
[TBL] [Abstract][Full Text] [Related]
5. Development of Complex Renal Cysts during Crizotinib Treatment and Also during Alectinib Treatment: A Possible Drug Class Effect?
Longo V; Catino AM; Montrone M; Pesola F; Pizzutilo P; Delbene G; Gatti P; Ferrante A; Galetta D
J Thorac Oncol; 2019 Aug; 14(8):e170-e172. PubMed ID: 31345340
[No Abstract] [Full Text] [Related]
6. [Renal cysts - A novel complication of crizotinib treatment for lung cancer].
CsToth I; Meert AP; Sculier JP; Berghmans T
Rev Mal Respir; 2015 Nov; 32(9):956-8. PubMed ID: 26033699
[TBL] [Abstract][Full Text] [Related]
7. [A case of crizotinib-associated renal cysts].
Quan LL; Huang P; Liang YC; Chen FW; Liu SB; Xin WW
Zhonghua Jie He He Hu Xi Za Zhi; 2024 Apr; 47(4):356-359. PubMed ID: 38599812
[TBL] [Abstract][Full Text] [Related]
8. Crizotinib-induced lichenoid drug eruption in a patient with lung cancer.
Ho YH; Chen CL
Cutis; 2018 Dec; 102(6):403-406. PubMed ID: 30657798
[TBL] [Abstract][Full Text] [Related]
9. Crizotinib-Induced Fulminant Hepatic Failure: A Rare Adverse Event.
Adhikari N; Kumar P; Venkatesulu BP; Pandey R; Haresh KP; Gupta S; Sharma DN; Rath GK
J Glob Oncol; 2018 Sep; 4():1-4. PubMed ID: 30241172
[No Abstract] [Full Text] [Related]
10. Successful treatment with brigatinib in a patient with ALK-rearranged lung adenocarcinoma who developed crizotinib-induced interstitial lung disease.
Doménech M; Jové M; Aso S; Marín M; Nadal E
Lung Cancer; 2018 May; 119():99-102. PubMed ID: 29656760
[TBL] [Abstract][Full Text] [Related]
11. Renal cyst formation in patients treated with crizotinib for non-small cell lung cancer-Incidence, radiological features and clinical characteristics.
Halpenny DF; McEvoy S; Li A; Hayan S; Capanu M; Zheng J; Riely G; Ginsberg MS
Lung Cancer; 2017 Apr; 106():33-36. PubMed ID: 28285691
[TBL] [Abstract][Full Text] [Related]
12. Regression of Crizotinib-Associated Complex Cystic Lesions after Switching to Alectinib.
Taima K; Tanaka H; Tanaka Y; Itoga M; Takanashi S; Tasaka S
Intern Med; 2017 Sep; 56(17):2321-2324. PubMed ID: 28794366
[TBL] [Abstract][Full Text] [Related]
13. Brigatinib versus crizotinib for ALK-positive NSCLC.
Stirrups R
Lancet Oncol; 2018 Nov; 19(11):e585. PubMed ID: 30293790
[No Abstract] [Full Text] [Related]
14. Development of renal cysts after crizotinib treatment in advanced ALK-positive non-small-cell lung cancer.
Lin YT; Wang YF; Yang JC; Yu CJ; Wu SG; Shih JY; Yang PC
J Thorac Oncol; 2014 Nov; 9(11):1720-5. PubMed ID: 25436806
[TBL] [Abstract][Full Text] [Related]
15. Regression of renal cyst in a NSCLC patient treated with crizotinib.
Okauchi S; Kawai K; Miyazaki K; Yamada H; Satoh H
Adv Respir Med; 2019; 87(3):201-202. PubMed ID: 31282565
[No Abstract] [Full Text] [Related]
16. Crizotinib Associated Renal Cysts [CARCs]: incidence and patterns of evolution.
Cameron LB; Jiang DH; Moodie K; Mitchell C; Solomon B; Parameswaran BK
Cancer Imaging; 2017 Feb; 17(1):7. PubMed ID: 28209203
[TBL] [Abstract][Full Text] [Related]
17. Severe Acute Hepatitis in a Patient Receiving Alectinib for ALK-Positive Non-Small-Cell Lung Cancer: Histologic Analysis.
Zhu VW; Lu Y; Ou SI
Clin Lung Cancer; 2019 Jan; 20(1):e77-e80. PubMed ID: 30318176
[No Abstract] [Full Text] [Related]
18. Successful Desensitization with Crizotinib after Crizotinib-induced Liver Injury in ROS1-rearranged Lung Adenocarcinoma.
Ota T; Masuda N; Matsui K; Yamada T; Tanaka N; Fujimoto S; Fukuoka M
Intern Med; 2019 Sep; 58(18):2651-2655. PubMed ID: 31178493
[TBL] [Abstract][Full Text] [Related]
19. Crizotinib-induced simultaneous multiple cardiac toxicities.
Oyakawa T; Muraoka N; Iida K; Kusuhara M; Kawamura T; Naito T; Takahashi T
Invest New Drugs; 2018 Oct; 36(5):949-951. PubMed ID: 29717400
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of ALK Tyrosine Kinase Inhibitors in Elderly Patients with Advanced ALK-Positive Non-Small Cell Lung Cancer: Findings from the Real-Life Cohort.
Bedas A; Peled N; Maimon Rabinovich N; Mishaeli M; Shochat T; Zer A; Rotem O; Allen AM; Bar J; Dudnik E;
Oncol Res Treat; 2019; 42(5):275-282. PubMed ID: 30955009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
